Osnat Elyashiv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Osnat Elyashiv has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan A. Ledermann
Department of Oncology, UCL Cancer Institute, University College London, London, UK
3 shared publications - Aarthi S. Jayraj
All India Institute of Medical Sciences, National Cancer Institute, Department of Gynaecologic Oncology, Jhajjar, India
2 shared publications - Alexander Shushkevich
Bodensee Klinikum, Department of Obstetrics and Gynecology, Friedrichshafen, Germany
2 shared publications - Andrej Cokan
Department of Gynaecological and Breast Oncology, University Medical Centre Maribor, 2000 Maribor, Slovenia
2 shared publications Anisa Mburu
2 shared publications- Emma Rose Allanson
Division of Obstetrics and Gynaecology, The University of Western Australia—Perth Campus, Perth, Western Australia, Australia
2 shared publications
Latest Publications
- 6 October 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (10)
Q-GOAL study: quality in gynecologic oncology advancement for learning: a global perspective
- 6 October 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (10)
Q-GOAL study: quality in gynecologic oncology advancement for learning: a global perspective
- 9 February 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (4) , 104554
Optimizing adjuvant treatment strategy in advanced clear cell endometrial cancer: systematic review and meta-analysis
- 9 February 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (4) , 104554
Optimizing adjuvant treatment strategy in advanced clear cell endometrial cancer: systematic review and meta-analysis
- 21 November 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (2) , 102809
Hormone replacement therapy in gynecologic cancer: oncologic safety and alternative therapies
- 21 November 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (2) , 102809
Hormone replacement therapy in gynecologic cancer: oncologic safety and alternative therapies
- 9 May 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (8) , 101931
IGCS 2024 Dublin: Highlights of research presented at the annual meeting
- 9 May 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (8) , 101931
IGCS 2024 Dublin: Highlights of research presented at the annual meeting
- 29 April 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (7) , 101913
Highlights from the 26th European Congress on Gynaecological Oncology in Rome: interview compilation of the ENYGO-IJGC editorial fellows
- 29 April 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (7) , 101913
Highlights from the 26th European Congress on Gynaecological Oncology in Rome: interview compilation of the ENYGO-IJGC editorial fellows
- Open Access
The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients
Objective: The goal of this study was to evaluate response to treatment and survival in epithelial ovarian cancer patients with acquired secondary platinum resistance (SPR) compared to patients with primary platinum resistance (PPR). Methods: Patients were categorized as PPR (patients with disease recurrence occurring during or p = 0.085). Also, no significant difference was found in post-platinum-resistant relapse survival, with a median of 17.63 months in the PPR and 20.26 months in the SPR group (p = 0.515). Conclusions: Platinum resistance is an important prognostic factor in women with EOC. Patients with SPR acquire the same poor treatment outcome as with PPR. There is a great need for future research efforts to discover novel strategies and biological treatments to reverse resistance and improve survival.
Open AccessThe Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients
Objective: The goal of this study was to evaluate response to treatment and survival in epithelial ovarian cancer patients with acquired secondary platinum resistance (SPR) compared to patients with primary platinum resistance (PPR). Methods: Patients were categorized as PPR (patients with disease recurrence occurring during or p = 0.085). Also, no significant difference was found in post-platinum-resistant relapse survival, with a median of 17.63 months in the PPR and 20.26 months in the SPR group (p = 0.515). Conclusions: Platinum resistance is an important prognostic factor in women with EOC. Patients with SPR acquire the same poor treatment outcome as with PPR. There is a great need for future research efforts to discover novel strategies and biological treatments to reverse resistance and improve survival.
- Open Access
- 4 October 2022
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 15, 1105-1117
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have revolutionised the management of patients with high-grade serous and endometrioid ovarian cancer demonstrating significant improvements in progression-free survival. Whilst the greatest benefit is seen with BRCA1/2 mutant cancers, it is clear that the benefit extends beyond this group. This sensitivity is thought to be due to homologous recombination deficiency (HRD), which is present in up to 50% of the high-grade serous cancers. Several different HRD assays exist, which fall into one of three main categories: homologous recombination repair (HRR)-related gene analysis, genomic “scars” and/or mutational signatures, and real-time HRD functional assessment. We review the emerging data on HRD as a predictive biomarker for PARP inhibitors and discuss the merits and disadvantages of different HRD assays.
- 4 October 2022
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 15, 1105-1117
Open AccessOvarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have revolutionised the management of patients with high-grade serous and endometrioid ovarian cancer demonstrating significant improvements in progression-free survival. Whilst the greatest benefit is seen with BRCA1/2 mutant cancers, it is clear that the benefit extends beyond this group. This sensitivity is thought to be due to homologous recombination deficiency (HRD), which is present in up to 50% of the high-grade serous cancers. Several different HRD assays exist, which fall into one of three main categories: homologous recombination repair (HRR)-related gene analysis, genomic “scars” and/or mutational signatures, and real-time HRD functional assessment. We review the emerging data on HRD as a predictive biomarker for PARP inhibitors and discuss the merits and disadvantages of different HRD assays.
- Open Access
- 14 June 2021
- Published by Springer Nature in Current Oncology Reports
- Vol. 23 (8) , 1-10
Frontline Maintenance Treatment for Ovarian Cancer
Purpose of Review: Advanced epithelial ovarian cancer remains the most lethal gynaecological cancer. Most patients with advanced disease will relapse within 3 years after primary treatment with surgery and chemotherapy. Recurrences become increasing difficult to treat due to the emergence of drug resistance and 5-year survival has changed little over the last decade. Maintenance treatment, here defined as treatment given beyond primary chemotherapy, can both consolidate the response and prolong the control of disease which is an approach to improve survival. Recent Findings: Here we review maintenance strategies such as targeting angiogenesis, interference of DNA repair through inhibition of PARP, combinations of targeting agents, and immunotherapy and hormonal therapy. Summary: Much has been learnt from the success and challenges of these treatments that have in the last few years which led to significant reduction in disease recurrence, changed the guidelines for treatment, and established a new paradigm for the treatment of ovarian cancer.
- 14 June 2021
- Published by Springer Nature in Current Oncology Reports
- Vol. 23 (8) , 1-10
Open AccessFrontline Maintenance Treatment for Ovarian Cancer
Purpose of Review: Advanced epithelial ovarian cancer remains the most lethal gynaecological cancer. Most patients with advanced disease will relapse within 3 years after primary treatment with surgery and chemotherapy. Recurrences become increasing difficult to treat due to the emergence of drug resistance and 5-year survival has changed little over the last decade. Maintenance treatment, here defined as treatment given beyond primary chemotherapy, can both consolidate the response and prolong the control of disease which is an approach to improve survival. Recent Findings: Here we review maintenance strategies such as targeting angiogenesis, interference of DNA repair through inhibition of PARP, combinations of targeting agents, and immunotherapy and hormonal therapy. Summary: Much has been learnt from the success and challenges of these treatments that have in the last few years which led to significant reduction in disease recurrence, changed the guidelines for treatment, and established a new paradigm for the treatment of ovarian cancer.
- 1 January 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (1) , 134-138
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Background Two novel biological agents—cediranib targeting angiogenesis, and olaparib targeting DNA repair processes—have individually led to an improvement in ovarian cancer control. The aim of ICON9 is to investigate the combination of cediranib and olaparib maintenance in recurrent ovarian cancer following platinum-based therapy. Primary objective To assess the efficacy of maintenance treatment with olaparib in combination with cediranib compared with olaparib alone following a response to platinum-based chemotherapy in women with platinum-sensitive ovarian, fallopian tube or peritoneal cancer during first relapse. Study hypothesis Maintenance therapy with cediranib and olaparib in combination is associated with improved patient outcomes compared with olaparib alone. Trial design International phase III randomized controlled trial. Following a response to platinum-based chemotherapy patients are randomized 1:1 to either oral olaparib and cediranib (intervention arm) or oral olaparib alone (control arm). Major inclusion criteria Patients with a known diagnosis of high grade serous or endometrioid carcinoma of the ovary, fallopian tube or peritoneum, progressing more than 6 months after first-line platinum-based chemotherapy, who have responded to second-line platinum-based chemotherapy. Primary endpoints Progression-free and overall survival. Co-primary endpoints to be assessed using a fixed-sequence gatekeeping approach: (1) progression-free survival, all patients; (2) progression-free survival, BRCA wild type; (3) overall survival, all patients; (4) overall survival, BRCA wild type. Sample size 618 patients will be recruited. Estimated dates for completing accrual and presenting results Accrual is expected to be completed in 2024 with presentation of results in 2025. Trial registration ClinicalTrials.gov: NCT03278717.
- 1 January 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (1) , 134-138
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Background Two novel biological agents—cediranib targeting angiogenesis, and olaparib targeting DNA repair processes—have individually led to an improvement in ovarian cancer control. The aim of ICON9 is to investigate the combination of cediranib and olaparib maintenance in recurrent ovarian cancer following platinum-based therapy. Primary objective To assess the efficacy of maintenance treatment with olaparib in combination with cediranib compared with olaparib alone following a response to platinum-based chemotherapy in women with platinum-sensitive ovarian, fallopian tube or peritoneal cancer during first relapse. Study hypothesis Maintenance therapy with cediranib and olaparib in combination is associated with improved patient outcomes compared with olaparib alone. Trial design International phase III randomized controlled trial. Following a response to platinum-based chemotherapy patients are randomized 1:1 to either oral olaparib and cediranib (intervention arm) or oral olaparib alone (control arm). Major inclusion criteria Patients with a known diagnosis of high grade serous or endometrioid carcinoma of the ovary, fallopian tube or peritoneum, progressing more than 6 months after first-line platinum-based chemotherapy, who have responded to second-line platinum-based chemotherapy. Primary endpoints Progression-free and overall survival. Co-primary endpoints to be assessed using a fixed-sequence gatekeeping approach: (1) progression-free survival, all patients; (2) progression-free survival, BRCA wild type; (3) overall survival, all patients; (4) overall survival, BRCA wild type. Sample size 618 patients will be recruited. Estimated dates for completing accrual and presenting results Accrual is expected to be completed in 2024 with presentation of results in 2025. Trial registration ClinicalTrials.gov: NCT03278717.
- 2 September 2019
- Published by Morressier GmbH
DO OVARIAN CANCER PATIENTS WITH PRIMARY OR SECONDARY PLATINUM RESISTANCE HAVE SIMILAR RESPONSE TO SUBSEQUENT CHEMOTHERAPY - RETROSPECTIVE COHORT STUDY
Background: Response to platinum-based chemotherapy is considered to be one of the most important prognostic factors in recurrent ovarian cancer. Women with primary platinum resistance (PPR) have poor prognosis. Less is known regarding outcome in patients with secondary, acquired platinum resistance (SPR). We evaluated response to treatment and survival in patients with PPR
- 2 September 2019
- Published by Morressier GmbH
DO OVARIAN CANCER PATIENTS WITH PRIMARY OR SECONDARY PLATINUM RESISTANCE HAVE SIMILAR RESPONSE TO SUBSEQUENT CHEMOTHERAPY - RETROSPECTIVE COHORT STUDY
Background: Response to platinum-based chemotherapy is considered to be one of the most important prognostic factors in recurrent ovarian cancer. Women with primary platinum resistance (PPR) have poor prognosis. Less is known regarding outcome in patients with secondary, acquired platinum resistance (SPR). We evaluated response to treatment and survival in patients with PPR